Comparative Pharmacology
Head-to-head clinical analysis: MOTOFEN versus XERMELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTOFEN versus XERMELO.
MOTOFEN vs XERMELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of diphenoxylate (opioid agonist) and atropine (anticholinergic). Diphenoxylate acts on μ-opioid receptors in the gut to slow peristalsis and reduce fluid secretion; atropine is added to discourage abuse by causing unpleasant anticholinergic effects at high doses.
Telotristat ethyl is a prodrug that is hydrolyzed to the active metabolite telotristat, an inhibitor of tryptophan hydroxylase (TPH). TPH is the rate-limiting enzyme in the peripheral conversion of tryptophan to serotonin. By inhibiting TPH, telotristat reduces serotonin production in the gut, thereby decreasing gastrointestinal motility and secretion, and reducing diarrhea associated with carcinoid syndrome.
1 to 2 tablets orally every 6 hours as needed, not to exceed 8 tablets per day.
250 mg orally three times daily with or without food.
None Documented
None Documented
Terminal elimination half-life: 20-24 hours; clinical context: once-daily dosing recommended
Terminal elimination half-life is approximately 6-10 hours in patients with carcinoid syndrome, supporting twice-daily dosing. In patients with moderate hepatic impairment, half-life may be prolonged to up to 19 hours.
Renal: ~60%; Fecal/Biliary: ~40%
Primarily excreted via feces (approximately 82% of absorbed dose) with a minor renal component (approximately 12% of absorbed dose as unchanged drug and metabolites).
Category C
Category C
Antidiarrheal
Antidiarrheal